|Articles|June 2, 2017

Preparing for the Growth of the Biopharma Market

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Is FDA Streamlining Regulations in the Biosimilar Space?

ByMike Hollan,Gillian Woollett

December 8th 2025

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

ByNicholas Saraceno, Editor

December 5th 2025

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

ByNicholas Jacobus

December 5th 2025

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

ByAndy Studna

December 4th 2025

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

ByNicholas Jacobus

December 4th 2025

Preparing for the Growth of the Biopharma Market

Newsletter

Related Content

Is FDA Streamlining Regulations in the Biosimilar Space?

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

Trending on PharmExec

Is FDA Streamlining Regulations in the Biosimilar Space?

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion